Literature DB >> 35103927

Hospitalization and mortality for acute exacerbation of asthma: an Italian population-based study.

Ombretta Para1, Andrea Montagnani2, Stefano Guidi3, Lorenza Bertù4, Dario Manfellotto5, Mauro Campanini6, Andrea Fontanella7, Francesco Dentali4.   

Abstract

Asthma is an ever-increasing disease with a highly variable prevalence among different ethnic groups. Information on hospital admission for acute exacerbation of asthma in adult patients and data regarding short-term prognosis of these patients are limited. We, thus, performed an epidemiological study on hospital admission for asthma acute exacerbation in Italy using hospital discharge database records derived from all Italian hospitals. Patients > 15 years old were identified using clinical Modification (ICD-9-CM) codes. Information on baseline characteristics, vital status at discharge, duration of hospitalization, and up to five secondary discharge diagnoses was collected. Comorbidity was evaluated using the Charlson comorbidity index (CCI). During the observation period (2013-2014), 20,056 patients with asthma acute exacerbation were hospitalized. Median length of hospitalization was 7.9 days (interquartile range 4-10) and mean in-hospital mortality was 0.8%. In-hospital mortality and length of hospitalization varied among different regions (from 0 to 2.9% and from 6.5 to 8.9 days, respectively). Old age, invasive and non-invasive mechanical ventilation, and CCI resulted as significantly associated with higher in-hospital mortality. Our study results, on a large sample of patients, confirm that hospitalization for asthma acute exacerbation is not uncommon among Italian current population. Older age, high CCI, and use of ventilator support were associated with a higher mortality rate. These findings should be analyzed to set up appropriate health care policies on patients with asthma.
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).

Entities:  

Keywords:  Asthma; Clinical modification codes; Exacerbation

Mesh:

Year:  2022        PMID: 35103927     DOI: 10.1007/s11739-021-02923-5

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   5.472


  5 in total

Review 1.  Asthma-related comorbidities.

Authors:  Louis-Philippe Boulet; Marie-Ève Boulay
Journal:  Expert Rev Respir Med       Date:  2011-06       Impact factor: 3.772

2.  Trends of asthma hospitalization and hospital mortality in mainland Portugal.

Authors:  N Santos; A Bugalho de Almeida; A Covas; L Prates; M Morais-Almeida
Journal:  Eur Ann Allergy Clin Immunol       Date:  2016-11

3.  Hospitalization and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD): an Italian population-based study.

Authors:  A Montagnani; G Mathieu; F Pomero; L Bertù; D Manfellotto; M Campanini; A Fontanella; B Sposato; F Dentali
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-06       Impact factor: 3.507

Review 4.  Noninvasive ventilation for acute exacerbations of asthma: A systematic review of the literature.

Authors:  Elyce Green; Paras Jain; Maree Bernoth
Journal:  Aust Crit Care       Date:  2017-01-27       Impact factor: 2.737

5.  Asthma length of stay in hospitals in London 2001-2006: demographic, diagnostic and temporal factors.

Authors:  Ireneous N Soyiri; Daniel D Reidpath; Christophe Sarran
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

  5 in total
  2 in total

1.  Persistent asthma hospitalisations and deaths require a national asthma prevention plan.

Authors:  Bianca Beghé; Leonardo Fabbri; Enrico Clini
Journal:  Intern Emerg Med       Date:  2022-05-17       Impact factor: 5.472

2.  Microarray-Based Analyses of Rhinovirus Species-Specific Antibody Responses in Exacerbated Pediatric Asthma in a German Pediatric Cohort.

Authors:  Erwan Sallard; Katarzyna Niespodziana; Maja Bajic; Thomas Schlederer; Peter Errhalt; Ann-Kathrin Behrendt; Stefan Wirth; Almut Meyer-Bahlburg; Anja Ehrhardt; Rudolf Valenta; Malik Aydin
Journal:  Viruses       Date:  2022-08-24       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.